Medical Simulation Medical Graphic
Medical Animation | MOA | Medical Illustration | Holo 3D | General 3D | Video Game Development | Contact

Biotechnology Animations – Biotechnology Illustrations

Clinical Animations / Trial Animations

Clinical Studies Animated Method of Action Video

Medical Animation Studio produces clinical animations and clinical illustrations.  Custom 3d trail illustrations and clinical illustrations for e learning can also be produced.   Biotechnology animations and biotechnology illustrations created for biotech companies and biotechnology marketing companies.
Biotechnology animated method of action video. 
Dr Nano
Medical Research Council and UCB join forces to offer access to UCB's novel antibody discovery platform
The Medical Research Council (MRC) and global pharmaceutical company UCB are to launch a collaboration that will provide UK scientists with access to cutting-edge technologies to discover new...
New study found three-month paliperidone palmitate significantly delayed time to relapse in patients with schizophrenia
Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to a new Phase 3...
Shionogi announces Naldemedine meets primary endpoint in a Phase 3 study for the treatment of opioid-induced constipation
Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co.
Results announced from the QUALIFY study in schizophrenia
Otsuka Pharmaceutical Europe Ltd. presented the results of the QUALIFY* study, which showed the superiority of Abilify Maintena compared to paliperidone palmitate when using the Heinrichs-Carpenter...
Anti-obesity treatment in animal models developed
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown that partial pharmacological inhibition of the PI3K enzyme in obese mice and monkeys reduces body weight and...
Preventative trial in arthritis to bring hope for millions, UK
A pioneering drug to be tested could bring hope to the millions of Britons who are likely to one day suffer from arthritis.
New data supporting Arno Therapeutics' HDAC inhibitor AR-42 published
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, has announced that data from a preclinical study demonstrate its...
Alzheimer's disease: Anavex presents positive results for both ANAVEX 2-73 and ANAVEX 3-71
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's and other central nervous system (CNS) diseases, pain and various types of...
Prostate cancer: Astellas announces new enzalutamide data
Astellas Pharma Europe Ltd. has announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an...
Boehringer Ingelheim's investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.
Results of Pfizer's community‐acquired pneumonia immunization trial in adults (CAPiTA) published
Findings from the Community‐Acquired Pneumonia Immunization Trial in Adults (CAPiTA), published in The New England Journal of Medicine, demonstrate that Prevenar 13®(pneumococcal...
Respiratory diseases: Interim results from new RPL554 trial demonstrates excellent drug tolerability even at highest dose
Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced encouraging interim results from the first part of a 120 subject...
Biogen Idec presents positive data for investigational Alzheimer's disease treatment aducanumab (BIIB037)
Biogen Idec has announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive...
Results from Phase III study evaluating oral otezla or injectable etanercept versus placebo in patients with moderate to severe plaque psoriasis
Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4)...
Oral Otezla (apremilast) long-term safety and efficacy data in patients with moderate to severe plaque psoriasis presented
Celgene Corporation has announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast) were presented at the 73rd...
WindowsFlashQuicktime
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2015
Content Management / Website Design by Tresware